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Abstract
The transcription factor C/EBPb controls differentiation, proliferation, and functionality of many cell types, including innate
immune cells. A detailed molecular understanding of how C/EBPb directs alternative cell fates remains largely elusive. A
multitude of signal-dependent post-translational modifications (PTMs) differentially affect the protean C/EBPb functions. In
this study we apply an assay that converts primary mouse B lymphoid progenitors into myeloid cells in order to answer the
question how C/EBPb regulates (trans-) differentiation and determines myeloid cell fate. We found that structural alterations
and various C/EBPb PTMs determine the outcome of trans-differentiation of lymphoid into myeloid cells, including different
types of monocytes/macrophages, dendritic cells, and granulocytes. The ability of C/EBPb to recruit chromatin remodeling
complexes is required for the granulocytic trans-differentiation outcome. These novel findings reveal that PTMs and
structural plasticity of C/EBPb are adaptable modular properties that integrate and rewire epigenetic functions to direct
differentiation to diverse innate immune system cells, which are crucial for the organism survival.
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Introduction
Understanding the molecular attributes and post-transcriptional
regulation of transcription factors in cell fate determination
remains a challenging task in molecular genetics and develop-
mental biology. Ectopic expression of some key transcription
factors can perturb cellular differentiation programs and install
new ones, such as during lymphoid to myeloid reprogramming or
trans-differentiation induced by CCAAT enhancer binding
proteins (C/EBPs) [1,2]. Trans-differentiation experiments may
help to determine plasticity of cell differentiation and how lineage
decisions are accomplished and epigenetically fixed, providing
important information for future regenerative medicine.
C/EBPs are gene regulators involved in many cell differenti-
ation and growth control processes in different cell types, including
cells from the hematopoietic system [3]. C/EBPb trans-differen-
tiates B lymphoid cells into inflammatory macrophages, activates
eosinophil genes in hematopoietic progenitors, acts as a pioneering
factor during dendritic cell (DC) specification and is involved in
emergency granulopoiesis [4,5,6,7,8,9,10]. C/EBPb orchestrates
cell type specification in combination with other transcription
factors and co-factors: C/EBPb together with c-Myb activates
myeloid genes in fibroblasts, together with PU.1 evokes macro-
phage differentiation, and together with TAL1 and FLI1 binds to
and establishes early priming of hematopoietic lineage genes
[11,12,13].
Structurally, C/EBPs contain N-terminal transactivation do-
mains (TAD), central regulatory domains (RD) and C-terminal
DNA-binding and leucine zipper dimerization domains (bZip).
The TAD and RD display modular designs with several highly
conserved regions (CRs) that are separated by polymorphic low
complexity regions (LCRs) [14,15]. C/EBPb is extensively
modified by post-translational modifications (PTMs), including
lysine acetylation, mono-, di-, tri-methylation, arginine mono- and
di-methylation, in addition to serine, threonine, and tyrosine
phosphorylation [3,15,16,17,18]. Moreover, alternative translation
initiation generates N-terminally truncated isoforms which further
multiplies C/EBPb diversity [18,19]. Natural N-terminal, or
experimental intra-molecular deletions or PTM site mutations
suggest modular, context specific functions of C/EBPb. The
emerging view is that multi-site modifications of C/EBPb integrate
extracellular signals to alter scaffolding functions for recruitment of
chromatin modulating complexes and the basic transcription
machinery [15,17,20,21].
To answer the emerging question about the importance of C/
EBPb structure and PTMs for determination of cell fate, here we
used an assay for trans-differentiation of primary B lymphoid into
myeloid cells [4,10]. We identified the essential requirement of a
core trans-activating region of C/EBPb that was previously shown
to interact in a regulated fashion with several transcription factors
and co-factors. Distinct C/EBPb PTM site or CR mutations
variegate reprogramming outcomes to yield cellular phenotypes
that correspond to at least four different myeloid cell types.
Interestingly, the granulocytic outcome depends on the capacity of
C/EBPb to recruit chromatin remodelers. Our data demonstrate
that a multitude of PTMs in connection with structural plasticity
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are pivotal for the fine-tuning of the epigenetic C/EBPb functions
to determine cell fate in the innate immune system.
Results and Discussion
The B cell to Myeloid Reprogramming Potential Resides
in the C/EBPb TAD
To identify C/EBPb structures involved in lympho-myeloid
trans-differentiation, primary B cell progenitors were purified from
wild type (WT) mouse bone marrow (. S1A) and retrovirally
infected with C/EBPb constructs, including the three C/EBPb
isoforms (LAP*, LAP, and LIP), as well as various CR
recombinants (Fig. 1, left panel). Infected cells were cultured
under conditions that support both B cell and myeloid cell
development [10] and surface marker expression alterations were
analyzed by flow cytometry (FACS) at 6 and 9 days post-infection
(dpi) to monitor reprogramming kinetics (Fig. 1 and S2A). Both the
LAP* and LAP C/EBPb isoforms up-regulated the myeloid
surface marker CD11b and down-regulated the B cell marker
CD19 at 6 and 9 dpi, indicating the gradual loss of the B cell
phenotype and completion of lympho-myeloid trans-differentia-
tion. In contrast, no significant change in the B cell phenotype was
observed in cells infected with the LIP C/EBPb isoform, similarly
to cells infected with MSCV vector or uninfected controls (Fig. 1
and S2A).
LAP* and LAP isoforms are distinguished by CR1, which
determines SWI/SNF chromatin remodeling complex recruitment
and differential regulation of gene subsets [20,22,23]. Omission of
CR1, as in the LAP isoform or in the CR2,3,4 mutant,
significantly decreased the kinetics of both acquisition of myeloid
and annulation of B cell features (Fig. 1, S2A and Table S1).
Deletion of CR1,2 or CR4 strongly compromised but did not
entirely abolish reprogramming, whereas removal of CR3 did not
affect trans-differentiation. Deletion of CR3,4 (DCR3,4) entirely
abrogated both activation of CD11b and repression of CD19,
however CR3,4 in combination with the bZIP was not sufficient
for reprogramming but required CR2 (CR2,3,4 in Fig. 1 and
S2A). The core trans-activating region of C/EBPb CR2,3,4 was
previously shown to interact in a regulated fashion with several
transcription factors and co-factors, including CBP/p300,
CARM1/PRMT4, G9a, TBP/TFIIB, Mediator, and several
other chromatin regulatory complex components
[20,21,22,24,25,26,27,28]. The LIP isoform, which lacks transac-
tivation potential and acts as a dominant negative inhibitor, not
only failed to induce myeloid conversion but also failed to down-
regulate B cell marker expression. Thus, activation of the myeloid
program and shutting down the B cell program both reside in the
C/EBPb TAD. As suppression of B cell fate involves removal of
Pax5 [10], one may therefore infer that inhibition of Pax5 occurs
through C/EBP mediated activation of a Pax5 inhibitor, co-
repressor, inhibitory RNA, or proteolysis.
Figure 1. Structural requirements for B cell to myeloid reprogramming potential of C/EBPb. Schematic representation of the different C/
EBPb constructs (left) indicating the conserved regions (CRs) in the transactivation domain (TAD; CR1,2,3,4; green, turquoise), regulatory domain (RD;
CR5,6,7; red), bZip domain (yellow), and the low complexity regions (LCRs, grey). Expression of lineage specific markers: B cell CD19 (red), myeloid
CD11b (blue), or double positive (magenta) at 6 (middle panel) or 9 dpi (right panel). Bar graph shows percentage of GFP+ gated (virus infected) cell
population; B cells - control uninfected GFP– B cell progenitors. Results represent mean 6 SEM from at least two experiments.
doi:10.1371/journal.pone.0065169.g001
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In many cell types C/EBPb is auto-repressed and becomes
activated by receptor tyrosine kinase ras/MAPK signaling,
resulting in acquisition of several C/EBPb PTMs and alterations
of protein interactions [14,16,21,25,29]. In fibroblasts and
erythroblastoid cells deletion of the repressive RD (DCR5,6,7)
enhanced myeloid gene activation by C/EBPb, whereas removal
of CR6 (DCR6) represented a dominant-negative mutant [14].
Surprisingly, both RD mutants DCR5,6,7 and DCR6 displayed
trans-differentiation potential similar to LAP*, suggesting that
regulation of C/EBPb in B cells may differ from other cell types.
The kinetics of myeloid trans-differentiation by a leucine-zipper
exchange mutant (CREB LZ) was found to be similar to WT,
suggesting that i) C/EBPb homodimers are able to reprogram B
cells, ii) the major trans-differentiation function of C/EBPb resides
in the TAD, and iii) both the bZip and the RD structures play
minor roles in lineage conversion. Notably, the reprogrammed
myeloid cells showed immunoglobulin gene rearrangement,
confirming their B cell origin (Fig. S1B).
To exclude auto-regulatory activation of endogenous C/EBPb
during lineage conversion C/EBPb deficient B cell progenitors
were tested. No differences between C/EBPb isoform or mutant
trans-differentiation capacity were observed between primary WT
and C/EBPb2/2 B cell progenitors (Fig. S2B compared to Fig. 1).
Likewise, no difference in the reprogramming capacity of C/EBPa
p42 was detected when WT and C/EBPb deficient B cells were
compared (Fig. S2C). Furthermore, the truncated C/EBPa p30
isoform, which lacks the C/EBPa TAD (equivalent to C/EBPb
CR2,3,4 TAD) failed to reprogram WT B cells, suggesting that
major reprogramming functions of both, C/EBPa and C/EBPb,
reside within their TADs. Therefore, C/EBPa- and C/EBPb-
mediated reprogramming are direct effects of the ectopically
expressed transcription factors.
Differential Regulation of Key Myeloid Genes by C/EBPb
WT and Mutants
To further analyze how the C/EBPb structure contributes to
myeloid gene expression, several pro-inflammatory M1, anti-
inflammatory M2 genes, and key regulators of macrophage
differentiation were examined by NanoString technology. RNA
expression analyses of C/EBPb2/2 B cell progenitors repro-
grammed by WT and mutant C/EBPb showed that many M1
genes and M2 genes became up-regulated during trans-differen-
tiation (Fig. 2). Hierarchical gene clustering indicated no
prevalence in M1 or M2 gene expression in reprogrammed cells
and an overlap but also differences between C/EBPb and C/
EBPa activated genes [4]. The C/EBPb isoform LAP* and the
deletion mutants DCR3 and DCR6 activated the majority of
analyzed genes. Other constructs, including LAP, DCR1,2 and
DCR4, showed lower or lacked trans-activation potential for
several M1 and M2 genes. Both, the LAP C/EBPb isoform and
the DCR1,2 mutant failed to up-regulate several macrophage
polarization genes, including Mmp12, Pparg, and Chi3l3, suggesting
that SWI/SNF recruitment through CR1 is a prerequisite for their
activation [20,22]. Several other genes (Cxcl10, Arg1, Maf) were up-
regulated by LAP but not by DCR1,2, suggesting that these genes
require CR2 functions that are distinct from SWI/SNF recruit-
ment. Finally, some genes (Il1b, Cxcl10, Ccl2, Arg1, Il4ra, Maf) were
more strongly activated by LAP than LAP*, in agreement with
isoform-specific gene regulatory functions [30]. On the other
hand, LAP* and several C/EBPb deletion mutants, but not LAP,
activated the expression of Mafb, whereas LAP was the strongest
activator of the Maf gene. In macrophage gene regulatory
circuitry, the lysine-specific demethylase 6B Kdm6b (Jmjd3) is
important for M2, but not for M1 polarization [31,32].
Interestingly, LAP and DCR1,2, which showed lower activation
of Kdm6b expression (3–6-fold) as compared to LAP*, both failed to
up-regulate Chi3l3, and DCR1,2 reprogrammed cells did also not
express Arg1 (Fig. 2). Hence, many myeloid genes displayed
designated C/EBPb CR-specific regulation, suggesting complex
combinatorial, locus specific relevance of distinct C/EBPb CRs in
gene regulation.
The C/EBPb Structure Determines Alternative Trans-
differentiation
Previously, it has been shown that C/EBPa or -b trans-
differentiate B cell progenitors only into inflammatory macro-
phages, characterized as CD11b+ F4/80+ Gr-1+ CD62L (L-
selectin)+ phenotype [10]. Phagocytosis assays performed with C/
EBPb reprogrammed CD11b+ cells, however, suggested cell
heterogeneity (Fig. S3A). In conjunction with the kaleidoscopic
myeloid gene regulation repertoire of C/EBPb mutants (Fig. 2),
this prompted us to explore the possibility of trans-differentiation
into distinct cell types. To this end, CD11b+ cells were examined
for expression of Gr-1/Ly-6C to distinguish between inflammatory
(CD11b+ Gr-1/Ly-6C+) and resident type (CD11b+ Gr-1/Ly-6C–)
monocytes/macrophages [33]. At 6 dpi the LAP* isoform
generated two CD11b+ subpopulations, with predominance of
CD11b+ Ly-6C+ cells and at 9 dpi the percentage of Ly-6C+ cells
significantly decreased at the expense of Ly-6C– cells (Table S2).
No differences in the frequency of apoptotic cells was observed
(Fig. S3B), suggesting that the reduction of Gr-1/Ly-6C+ cells was
not caused by selective cell death. Interestingly, C/EBPb
constructs that lacked CR1 (LAP, CR2,3,4, DCR1,2) induced less
Ly-6C+ cells, while others (DCR6) strongly induced Ly-6C+ cells at
both 6 and 9 dpi (Table S2). These results suggested not only cell
heterogeneity but also that the C/EBPb structure might determine
the myeloid phenotype.
Ly-6C/Gr-1 expression distinguishes inflammatory from resi-
dent monocytes/macrophages [33]. Lack of MCSF-R could serve
to discriminate granulocytes from monocytes/macrophages, how-
ever, as MCSF-R is also a direct C/EBPb target gene [34], Ly-6G
was included as a neutrophil granulocytic surface marker [35].
Based on the expression of Ly-6C, MCSF-R, and Ly-6G, the C/
EBPb-LAP* reprogrammed CD11b+ cells consisted of four cell
subpopulations: resident monocytes/macrophages (Ly-6C– M-
CSFR+), neutrophil granulocytes (Ly-6C+ Ly-6G+), and Ly-6C–
M-CSFR– cells (Fig. 3A, B), in addition to the previously shown
inflammatory monocytes/macrophages (Ly-6C+ Ly-6G–) [10].
The Ly-6C– M-CSFR– cells were further analyzed and classified
as CD11c+ MHC-II+/++ CD86+/med, suggesting conventional
dendritic (cDC) phenotype (Fig. 3C) [36]. The percentage of
inflammatory monocyte/macrophages decreased between 6 and
9 dpi, whereas the percentage of resident monocytes/macrophag-
es increased (Fig. S3C). This is most likely due to differentiation of
inflammatory monocytes/macrophages into resident ones [33].
Cyto-morphological examination of the LAP*-reprogrammed cells
confirmed FACS data and revealed the presence of cells with
morphological characteristics of polymorphonuclear neutrophils,
monocytes/DCs, and macrophages (Fig. 3D), whereas the MSCV
control or C/EBPb constructs incapable of inducing CD11b
expression (such as LIP, DCR3,4, CR3,4) displayed B cell
phenotype (Fig. 3). No granulocytic differentiation and only few
inflammatory monocytes/macrophage were obtained by con-
structs lacking CR1, such as LAP, CR2,3,4 and DCR1,2
(Figure 3A, B, D and S3C). In contrast, deletion of CR6 led to
an increase in the neutrophil granulocytic population (Fig. 3A, B,
D). Interestingly, the augmented granulocytic differentiation
correlated with decreased DC differentiation (Fig. 3A, B, C).
C/EBPb Modifications and Myeloid Reprogramming
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Based on myeloid surface marker expression and cell morphology,
we conclude that structural alterations in C/EBPb pre-define the
reprogramming outcomes into inflammatory and resident mono-
cytes/macrophages, cDC-like cells, and granulocytes.
Mechanistically, differences between LAP* and LAP have
previously been attributed to differentially regulated SWI/SNF
recruitment. LAP*-specific CR1 functions and the activity of the
TAD have been shown to be negatively regulated by CARM1/
PRMT4 and G9a methylation of R3 and K39, respectively
[20,22,27]. Furthermore, CR1 was reported to control SUMOy-
lation [30], thus integrating various signals to yield epigenetic
consequences. Accordingly, we refined the trans-differentiation
analysis using C/EBPb point mutants that affect the above
mentioned modification sites. As shown in Figure 4, amino acid
substitution of the G9a K39 methylation sites or the UBC9
binding/SUMOylation/methylation sites K156A/E158A, en-
hanced granulocytic trans-differentiation, similar to DCR6
(Fig. 3). The LAP* R3L mutant, which mimics the R3 methylated
state, abrogated SWI/SNF recruitment, and failed to induce the
neutrophil elastase gene [20], strongly decreased granulocytic
trans-differentiation, whereas the LAP* R3A mutant, which
abrogates methylation, maintained granulocytic trans-differentia-
tion (Fig. 4). Therefore, decoration of C/EBPb with PTMs
modifies its trans-differentiation capacity and, in agreement with
other data [37], that recruitment of chromatin remodeling
complexes through CR1 is required for granulocytic differentia-
tion (Fig. 4E).
Advancing our understanding of the importance of transcription
factor regulation and PTMs in lineage decisions is instrumental to
elucidate normal development and aberrant epigenetic processes
in connection with disease. Previous findings have suggested that
chromatin regulatory factors and epigenetic state regulation are
involved in hematopoietic cell decisions [37,38]. Furthermore, it
has been shown that interactions between C/EBPb and the
transcriptional and epigenetic machineries are controlled by C/
EBPb PTMs [15,17,18,20,21,22,25,27] but their importance for
directing differential myeloid cell differentiation is quite obscure.
The B cell to myeloid lineage conversion now connects C/EBPb
PTMs to alternative cell fate instruction, raising the possibility that
related mechanisms control regular myelopoiesis. Although we do
not imply B cell to myeloid trans-differentiation as a frequent
event, it recalls the evolutionary relationship between innate and
acquired immunity [39,40,41,42]. Moreover, lineage switching of
B cell lymphoma to acute monoblastic leukemia or trans-
differentiation of follicular lymphoma to histiocytic/DC sarcomas
have been reported [43,44] and bi-phenotypic lymphoma
displayed functional dependency on high C/EBPb expression
[45,46,47]. These data suggest a role of lympho-myeloid plasticity
in malignant transformation. It is evident that more detailed
mechanistic insight in spatio-temporal modifications and co-factor
recruitment requires advanced tools, such as generation of knock-
in mouse mutants, determination of the PTM-dependent C/EBPb
interactome, PTM specific antibodies and genome wide compar-
ison of C/EBPb mutant binding. Nevertheless, the extensive
Figure 2. C/EBPb WT and mutants differentially regulate key myeloid genes. RNA counts for pro-inflammatory M1, anti-inflammatory M2
and other key monocyte/macrophage genes evaluated on CD11b+ reprogrammed C/EBPb2/2 B cell progenitors. Data were calculated as log2 and
subjected to hierarchical clustering. Results represent expression profiles from three independent experiments. On the right, comparison to data
obtained from reprogramming of pre-B cell line by C/EBPa is presented (Bussmann et al., 2009). MPh - WT bone marrow-derived macrophages.
doi:10.1371/journal.pone.0065169.g002
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decoration with PTMs in conjunction with reprogramming data
provided here suggest that C/EBPb integrates extracellular signals
to accomplish alternative differentiation into diverse cells of the
innate immune system.
Figure 3. C/EBPb structural mutants define distinct myeloid cell trans-differentiation outcomes. A. Representative FACS plots depicting
the expression of myeloid cell markers Ly-6C, M-CSFR, and Ly-6G on 9 days trans-differentiated cells. FACS plots represent GFP+ CD11b+ cell
populations, for MSCV control - GFP+ CD19+ cells. B. Distribution of the myeloid subpopulations among the reprogrammed GFP+ CD11b+ cells after
staining as in A and presented as mean 6 SEM. N - number of repetitions. Gr - neutrophil granulocytes, iM and rM - inflammatory and resident
monocytes/macrophages, respectively, DC - dendritic cells. C. Expression of the DC markers CD11c, MHC-II and CD86 on the reprogrammed Ly-6C– M-
CSFR– cells. Histograms represent GFP+ CD11b+ Ly-6C– M-CSFR– gated cells (color coded as the corresponding population on the Ly-6C/M-CSFR plot
in A). ‘‘++’’, ‘‘+’’, ‘‘med’’ and ‘‘2’’ represent the expression levels of MHC-II and CD86 antigens. D. Cytospins of control MSCV infected CD19+ cells and
CD11b+ cells reprogrammed by WT C/EBPb or deletion mutants. B – B cells, M – macrophages, Gr – neutrophil granulocytes, * - monocytes/DCs.
doi:10.1371/journal.pone.0065169.g003
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Materials and Methods
Ethics Statement
All mice were bred and maintained in accordance with
guidelines from institutional Animal Care Committee under
specific pathogen-free animal facilities at the MDC/Charite´.
Experiments were approved by the Commission for Animal
Experiments at the MDC and the Berlin Office of Health
(LAGeSo), Permit Number T 0339/08. For isolation of cells, mice
were sacrificed by euthanasia using carbon dioxide inhalation
followed by cervical dislocation. All efforts were made to minimize
animal suffering.
Mouse Strains, Cell Sorting and FACS Analyses
Primary B cell progenitors were obtained from bone marrow of
3–6 months old C57BL/6 or C/EBPb2/2 mice [48]. After
erythrolysis, cells were incubated with non-B cell lineage (Lin)
biotin-coupled antibodies against Gr-1 (RB6-8C5), CD11b (M1/
70), CD4 (GK1.5), CD8 (53-6.7), TER-119 (TER-119), and
CD49b (DX5) (Biolegend) and Lin+ cells were depleted using
Dynabeads sheep anti-Rat IgG (Invitrogen). Cells were then
stained with B220-PE Cy7 (RA3-6B2), CD19-FITC (6D5), Gr-1-
PE (RB6-8C5), SA-APC Cy7 (Biolegend), IgM-APC (II/41) (BD
Pharmingen), and DAPI and Lin– B220+ IgM– CD19+/2 pre-pro/
pro/pre B cells were sorted by FACS.
For the FACS analyses, after Fc blocking with rat anti-mouse
CD16/32 antibody (BD Pharmingen) cells were stained with the
following antibodies: rat anti-mouse CD11b-PerCP Cy5.5 (M1/
70), CD11b-APC Cy7 (M1/70), CD11b-PE (M1/70), CD19-APC
(6D5), CD19-PE Cy7 (6D5), CD45-PE Cy7 (30-F11), Gr-1-APC
Cy7 (RB6-8C5), Ly-6C-APC Cy7 (HK1.4), Ly-6G-APC (1A8),
CD115-PE (M-CSFR, Cl. AFS98), CD115-APC (M-CSFR, Cl.
AFS98), F4/80-Pacific blue (A3-1), MHC-II-PE (I-A/I-E, Cl. M5/
114.15.2) (all from Biolegend), CD86-PE (B7-2), hamster anti-
Figure 4. C/EBPb PTM site mutations affect lympho-myeloid trans-differentiation. A. Schematic representation of C/EBPb PTM sites and
mutants tested in B-D. B. Expression of Ly-6C, M-CSFR and Ly-6G on the reprogrammed cells at 9 dpi. C. Distribution of the different myeloid
populations among the reprogrammed GFP+ CD11b+ cells, stained as in B and presented as mean 6 SEM. D. Cytospins of trans-differentiated sorted
cells. Experiments were repeated two to three times and similar results were obtained. Gating strategies and abbreviations as in Fig. 3. E. Schematic
representation of the normal hematopoiesis and lympho-myeloid reprogramming by C/EBPb. MPP - multi potent progenitors, CLP - common
lymphoid progenitor, CMP - common myeloid progenitor, GMP - granulocyte/macrophage progenitor, iMW and rMW - inflammatory and resident
monocytes/macrophages.
doi:10.1371/journal.pone.0065169.g004
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mouse CD11c-APC (HL3) and CD11c-V450 (HL3) (BD Pharmin-
gen). 7-AAD (BD Pharmingen) or DAPI (Invitrogen, Molecular
probes) were added to discriminate cell viability. Samples were run
on FACS Canto machine (BD Biosciences, BD Diva Software) and
analyzed with FlowJo software.
Retroviral Vectors, Infection and Cell Culture
The C/EBPb (GI:148539989) LAP* start site was optimized
regarding the Kozak consensus sequence and CR-deletion
mutants were published before [14]. C/EBPb point mutations
were obtained by site directed mutagenesis using the QuikChange
site-directed mutagenesis kit (Stratagene). All C/EBP constructs
were cloned into the MIEG3 (MSCV-IRES-EGFP) retroviral
vector. Purified B cell progenitors were seeded at 26105 cells/ml
in IMDM medium with 20% hiFCS, 50 mM 2-mercaptoethanol
(Invitrogen) and 10 ng/ml IL-7, SCF, Flt-3L, and infected with
viral supernatant plus polybrene (Sigma; 8 mg/ml) [10]. Infected
cells were transferred into HTS Transwell-24 well (Corning)
supplemented with 10 ng/ml IL-7, SCF, Flt-3L, IL-3 and M-CSF
(Peprotech) and co-cultured with S17 cells [49] pretreated with
10 mg/ml mitomycin. Expression of C/EBPb constructs was
determined by GFP cytofluorometric read-out, correct protein
sizes were assessed by immunobloting, and intracellular protein
staining confirmed expression of C/EBPb proteins in the
retrovirally infected primary B cell progenitors (Fig. S1C, D).
Cytospins
GFP+ CD11b+ and GFP+ CD19+ cells were sorted by FACS
9 days after retroviral infection and cytospins were performed.
Slides were fixed in 100% methanol and stained with May-
Grunwald and Giemsa (Sigma).
RNA Extraction and mRNA Expression Analysis by
Nanostring Technology
Total RNA was extracted from C/EBPb2/2 B cell progenitors
6 days after infection with C/EBPb constructs and sorting of the
CD11b+ reprogrammed cells or from bone marrow-derived
macrophages (control, 6 days in vitro cultured) using RNeasy
Micro Kit (QIAGEN) according to the manufacture’s recommen-
dations. mRNA counts were determined using Nanostring
technology [50] after background subtraction and normalization
to three house-keeping genes (Gapdh, Tbp, Ppia). Expression below
the background level was set to value ‘‘1’’. After log2 transforma-
tion, data were subjected to hierarchical clustering using Euclidean
Distance to generate a gene and sample tree (MeV software).
Statistical Analysis
In all experiments, data are presented as mean 6 SEM
(standard error of the mean). Statistical analyses were done on
Prism 4.0a (GraphPad Software) applying unpaired two-tailed t
test for the calculation of the P-value. The statistical significance of
the P-value was defined as: P.0.05 - not significant, P = 0.01–0.05
- significant (*), P = 0.001–0.01 - very significant (**), P,0.001 -
extremely significant (***).
More Materials and Methods could be found in theMaterials
and Methods S1.
Supporting Information
Figure S1 FACS sorting strategy, rearrangements in
IgH gene loci and C/EBPb expression in the C/EBPb
reprogrammed myeloid cells (related to Figure 1). A.
Bone marrow single cell suspension was prepared and cells stained,
as described in Materials and Methods. Lin– B220+ IgM– CD19+/
2 pre-pro/pro/pre B cell progenitors were sorted for the
reprogramming experiments. Lin+ cells were cultured in vitro for
obtaining bone marrow-derived macrophages (MPh) for negative
controls for IgH rearrangement PCR. Lin– B220+ IgM+ bone
marrow immature B cells and spleenic B220+ B cells were sorted
for positive rearrangement PCR controls. B. PCR for D-J
rearrangements in IgH locus. CD11b+ reprogrammed myeloid
cells and CD19+ MSCV-, LIP- and DCR3,4-infected B cells were
sorted and PCR for D-J rearrangements in the IgH locus was
performed. Controls: WT bone marrow-derived macrophages
(MPh) and spleenic B cells. Data shown are representative from
multiple experiments. C. Protein expression of the C/EBPb WT
and deletion constructs in the virus-packaging cell line PlatE. The
size of the proteins is according to the size of the deletions. D.
Intracellular C/EBPb protein staining in the reprogrammed cells.
The relative C/EBPb expression in the virus-infected cells was
calculated as described in Materials and Methods S1. The
endogenous C/EBPb expression level in WT bone marrow-
derived macrophages (MPh) was also assessed. The relative C/
EBPb expression values varied between the different experiments,
however the tendencies were highly reproducible.
(TIF)
Figure S2 Reprogramming of WT and C/EBPb2/2 B cell
progenitors by C/EBPa and C/EBPb (related to
Figure 1). A. Representative FACS profiles of the C/EBPb
infected WT B cell progenitors at 6 and 9 dpi. FACS plots
represent GFP+ gated cell population, B cells - control uninfected
GFP– B cell progenitors. Similar outcomes were obtained from at
least two repeat experiments. B. Percentage of C/EBPb2/2 B cell
progenitors infected with C/EBPb WT and mutants expressing
the B cell marker CD19 or the myeloid marker CD11b at 6 dpi.
Intermediates (CD19+ CD11+ cells) are also included. Graphs
represent GFP+ gated cell population, B cells - control uninfected
GFP– B cell progenitors. Values represent mean 6 SEM from two
and more repeat experiments. C. Percentage of WT and C/
EBPb2/2 B cell progenitors infected with WT C/EBPa p42 and
p30 expressing the B cell marker CD19 or the myeloid marker
CD11b at 6 dpi. Intermediates (CD19+ CD11+ cells) are also
included. Graphs represent GFP+ gated cell population. Values for
C/EBPb2/2 B cell progenitors represent mean6 SEM from three
repeat experiments.
(TIF)
Figure S3 Heterogeneity among reprogrammed mye-
loid cells and lack of differential apoptosis between the
subpopulations of reprogrammed cells (related to
Figure 3). A. Phagocytosis assay was performed after 10 days
in vitro reprogramming. Red line represents cells incubated with
fluorescent latex beads and the black line - the auto-fluorescence of
the untreated samples. For MSCV-infected cells histograms
represent GFP+ CD19+ population, whereas C/EBPb-infected
reprogrammed cells were gated on GFP+ CD11b+ cells. As positive
controls for phagocytic capacity, bone marrow-derived macro-
phages (MPh) were used. Similar outcomes were obtained in two
or more repeat experiments. B. Apoptosis assay based on
AnnexinV staining and evaluated by FACS. Dead cells were
excluded by DAPI staining and the apoptosis assessment was done
after gating on the different GFP+ cell populations (CD19+,
CD11b+ Gr-1– and CD11b+ Gr-1+). na – no available cells with
these surface characteristics. The graph represents data from four
independent experiments. C. Expression of Ly-6C and M-CSFR
myeloid cell markers on the reprogrammed cells at 6 and 9 dpi.
FACS plots represent GFP+ CD11b+ cell population. For MSCV-
infected cells FACS plots represent GFP+ CD19+ cells. The
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myeloid cell marker staining was repeated in at least two
independent experiments and similar results were obtained.
(TIF)
Table S1 C/EBPb WT and mutant constructs display
different B-to-myeloid cell reprogramming kinetics
(related to Figure 1).
(DOC)
Table S2 Differential Ly-6C expression on CD11b+ cells
reprogrammed by WT and mutant C/EBPb (related to
Figure 3).
(DOC)
Materials and Methods S1 Supplementary Materials
and Methods
(DOC)
Acknowledgments
We acknowledge D. Kunkel (BCRT Flow Cytometry Lab) and T. Graf for
providing S17 cells. We thank V. Be´gay, B. Cirovic, S. Kaufer, G. Regalo,
and J. Scho¨nheit for scientific discussions and comments on the
manuscript. We thank A. Schulze, N. Haritonow, A. Klevesath for
technical assistance.
Author Contributions
Conceived and designed the experiments: BS EKL MS AL. Performed the
experiments: BS EKL. Analyzed the data: BS EKL MS AL. Contributed
reagents/materials/analysis tools: EKL MS. Wrote the paper: BS AL.
References
1. Graf T (2011) Historical origins of transdifferentiation and reprogramming. Cell
stem cell 9: 504–516.
2. Laiosa CV, Stadtfeld M, Graf T (2006) Determinants of lymphoid-myeloid
lineage diversification. Annual review of immunology 24: 705–738.
3. Tsukada J, Yoshida Y, Kominato Y, Auron PE (2011) The CCAAT/enhancer
(C/EBP) family of basic-leucine zipper (bZIP) transcription factors is a
multifaceted highly-regulated system for gene regulation. Cytokine 54: 6–19.
4. Bussmann LH, Schubert A, Vu Manh TP, De Andres L, Desbordes SC, et al.
(2009) A robust and highly efficient immune cell reprogramming system. Cell
stem cell 5: 554–566.
5. Garber M, Yosef N, Goren A, Raychowdhury R, Thielke A, et al. (2012) A high-
throughput chromatin immunoprecipitation approach reveals principles of
dynamic gene regulation in mammals. Molecular cell 47: 810–822.
6. Hirai H, Kamio N, Huang G, Matsusue A, Ogino S, et al. (2013) Cyclic AMP
Responsive Element Binding Proteins Are Involved in ‘Emergency’ Granulo-
poiesis through the Upregulation of CCAAT/Enhancer Binding Protein beta.
PloS one 8: e54862.
7. Hirai H, Zhang P, Dayaram T, Hetherington CJ, Mizuno S, et al. (2006) C/
EBPbeta is required for ‘emergency’ granulopoiesis. Nature immunology 7: 732–
739.
8. Muller C, Kowenz-Leutz E, Grieser-Ade S, Graf T, Leutz A (1995) NF-M
(chicken C/EBP beta) induces eosinophilic differentiation and apoptosis in a
hematopoietic progenitor cell line. The EMBO journal 14: 6127–6135.
9. Nerlov C, McNagny KM, Doderlein G, Kowenz-Leutz E, Graf T (1998)
Distinct C/EBP functions are required for eosinophil lineage commitment and
maturation. Genes & development 12: 2413–2423.
10. Xie H, Ye M, Feng R, Graf T (2004) Stepwise reprogramming of B cells into
macrophages. Cell 117: 663–676.
11. Feng R, Desbordes SC, Xie H, Tillo ES, Pixley F, et al. (2008) PU.1 and C/
EBPalpha/beta convert fibroblasts into macrophage-like cells. Proceedings of
the National Academy of Sciences of the United States of America 105: 6057–
6062.
12. Lichtinger M, Ingram R, Hannah R, Muller D, Clarke D, et al. (2012) RUNX1
reshapes the epigenetic landscape at the onset of haematopoiesis. The EMBO
journal 31: 4318–4333.
13. Ness SA, Kowenz-Leutz E, Casini T, Graf T, Leutz A (1993) Myb and NF-M:
combinatorial activators of myeloid genes in heterologous cell types. Genes &
development 7: 749–759.
14. Kowenz-Leutz E, Twamley G, Ansieau S, Leutz A (1994) Novel mechanism of
C/EBP beta (NF-M) transcriptional control: activation through derepression.
Genes & development 8: 2781–2791.
15. Leutz A, Pless O, Lappe M, Dittmar G, Kowenz-Leutz E (2011) Crosstalk
between phosphorylation and multi-site arginine/lysine methylation in C/EBPs.
Transcription 2: 3–8.
16. Lee S, Shuman JD, Guszczynski T, Sakchaisri K, Sebastian T, et al. (2010)
RSK-mediated phosphorylation in the C/EBP{beta} leucine zipper regulates
DNA binding, dimerization, and growth arrest activity. Molecular and cellular
biology 30: 2621–2635.
17. Nerlov C (2008) C/EBPs: recipients of extracellular signals through proteome
modulation. Current opinion in cell biology 20: 180–185.
18. Zahnow CA (2009) CCAAT/enhancer-binding protein beta: its role in breast
cancer and associations with receptor tyrosine kinases. Expert reviews in
molecular medicine 11: e12.
19. Calkhoven CF, Muller C, Leutz A (2000) Translational control of C/EBPalpha
and C/EBPbeta isoform expression. Genes & development 14: 1920–1932.
20. Kowenz-Leutz E, Pless O, Dittmar G, Knoblich M, Leutz A (2010) Crosstalk
between C/EBPbeta phosphorylation, arginine methylation, and SWI/SNF/
Mediator implies an indexing transcription factor code. The EMBO journal 29:
1105–1115.
21. Lee S, Miller M, Shuman JD, Johnson PF (2010) CCAAT/Enhancer-binding
protein beta DNA binding is auto-inhibited by multiple elements that also
mediate association with p300/CREB-binding protein (CBP). The Journal of
biological chemistry 285: 21399–21410.
22. Kowenz-Leutz E, Leutz A (1999) A C/EBP beta isoform recruits the SWI/SNF
complex to activate myeloid genes. Molecular cell 4: 735–743.
23. Uematsu S, Kaisho T, Tanaka T, Matsumoto M, Yamakami M, et al. (2007)
The C/EBP beta isoform 34-kDa LAP is responsible for NF-IL-6-mediated gene
induction in activated macrophages, but is not essential for intracellular bacteria
killing. Journal of immunology 179: 5378–5386.
24. Mink S, Haenig B, Klempnauer KH (1997) Interaction and functional
collaboration of p300 and C/EBPbeta. Molecular and cellular biology 17:
6609–6617.
25. Mo X, Kowenz-Leutz E, Xu H, Leutz A (2004) Ras induces mediator complex
exchange on C/EBP beta. Molecular cell 13: 241–250.
26. Nerlov C, Ziff EB (1995) CCAAT/enhancer binding protein-alpha amino acid
motifs with dual TBP and TFIIB binding ability co-operate to activate
transcription in both yeast and mammalian cells. The EMBO journal 14:
4318–4328.
27. Pless O, Kowenz-Leutz E, Knoblich M, Lausen J, Beyermann M, et al. (2008)
G9a-mediated lysine methylation alters the function of CCAAT/enhancer-
binding protein-beta. The Journal of biological chemistry 283: 26357–26363.
28. Steinberg XP, Hepp MI, Fernandez Garcia Y, Suganuma T, Swanson SK, et al.
(2012) Human CCAAT/enhancer-binding protein beta interacts with chroma-
tin remodeling complexes of the imitation switch subfamily. Biochemistry 51:
952–962.
29. Williams SC, Baer M, Dillner AJ, Johnson PF (1995) CRP2 (C/EBP beta)
contains a bipartite regulatory domain that controls transcriptional activation,
DNA binding and cell specificity. The EMBO journal 14: 3170–3183.
30. Eaton EM, Sealy L (2003) Modification of CCAAT/enhancer-binding protein-
beta by the small ubiquitin-like modifier (SUMO) family members, SUMO-2
and SUMO-3. The Journal of biological chemistry 278: 33416–33421.
31. Ishii M, Wen H, Corsa CA, Liu T, Coelho AL, et al. (2009) Epigenetic
regulation of the alternatively activated macrophage phenotype. Blood 114:
3244–3254.
32. Satoh T, Takeuchi O, Vandenbon A, Yasuda K, Tanaka Y, et al. (2010) The
Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses
against helminth infection. Nature immunology 11: 936–944.
33. Sunderkotter C, Nikolic T, Dillon MJ, Van Rooijen N, Stehling M, et al. (2004)
Subpopulations of mouse blood monocytes differ in maturation stage and
inflammatory response. Journal of immunology 172: 4410–4417.
34. Krysinska H, Hoogenkamp M, Ingram R, Wilson N, Tagoh H, et al. (2007) A
two-step, PU.1-dependent mechanism for developmentally regulated chromatin
remodeling and transcription of the c-fms gene. Molecular and cellular biology
27: 878–887.
35. Rose S, Misharin A, Perlman H (2012) A novel Ly6C/Ly6G-based strategy to
analyze the mouse splenic myeloid compartment. Cytometry Part A : the journal
of the International Society for Analytical Cytology 81: 343–350.
36. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, et al. (2010)
Development of monocytes, macrophages, and dendritic cells. Science 327: 656–
661.
37. Vradii D, Wagner S, Doan DN, Nickerson JA, Montecino M, et al. (2006) Brg1,
the ATPase subunit of the SWI/SNF chromatin remodeling complex, is
required for myeloid differentiation to granulocytes. Journal of cellular
physiology 206: 112–118.
38. Wada T, Kikuchi J, Nishimura N, Shimizu R, Kitamura T, et al. (2009)
Expression levels of histone deacetylases determine the cell fate of hematopoietic
progenitors. The Journal of biological chemistry 284: 30673–30683.
39. Cumano A, Paige CJ, Iscove NN, Brady G (1992) Bipotential precursors of B
cells and macrophages in murine fetal liver. Nature 356: 612–615.
40. Katoh S, Tominaga A, Migita M, Kudo A, Takatsu K (1990) Conversion of
normal Ly-1-positive B-lineage cells into Ly-1-positive macrophages in long-
term bone marrow cultures. Dev Immunol 1: 113–125.
C/EBPb Modifications and Myeloid Reprogramming
PLOS ONE | www.plosone.org 8 June 2013 | Volume 8 | Issue 6 | e65169
41. Kawamoto H, Katsura Y (2009) A new paradigm for hematopoietic cell
lineages: revision of the classical concept of the myeloid-lymphoid dichotomy.
Trends Immunol 30: 193–200.
42. Takahashi K, Miyakawa K, Wynn AA, Nakayama K, Myint YY, et al. (1998)
Effects of granulocyte/macrophage colony-stimulating factor on the develop-
ment and differentiation of CD5-positive macrophages and their potential
derivation from a CD5-positive B-cell lineage in mice. Am J Pathol 152: 445–
456.
43. Feldman AL, Arber DA, Pittaluga S, Martinez A, Burke JS, et al. (2008) Clonally
related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence
for transdifferentiation of the follicular lymphoma clone. Blood 111: 5433–5439.
44. Muroi K, Imagawa S, Suzuki T, Amemiya Y, Miura Y (1995) B-cell lymphoma
terminating in acute monoblastic leukemia. Internal medicine 34: 36–38.
45. Anastasov N, Bonzheim I, Rudelius M, Klier M, Dau T, et al. (2010) C/
EBPbeta expression in ALK-positive anaplastic large cell lymphomas is required
for cell proliferation and is induced by the STAT3 signaling pathway.
Haematologica 95: 760–767.
46. Jundt F, Raetzel N, Muller C, Calkhoven CF, Kley K, et al. (2005) A rapamycin
derivative (everolimus) controls proliferation through down-regulation of
truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity
in Hodgkin and anaplastic large cell lymphomas. Blood 106: 1801–1807.
47. Piva R, Pellegrino E, Mattioli M, Agnelli L, Lombardi L, et al. (2006) Functional
validation of the anaplastic lymphoma kinase signature identifies CEBPB and
BCL2A1 as critical target genes. J Clin Invest 116: 3171–3182.
48. Sterneck E, Tessarollo L, Johnson PF (1997) An essential role for C/EBPbeta in
female reproduction. Genes & development 11: 2153–2162.
49. Collins LS, Dorshkind K (1987) A stromal cell line from myeloid long-term bone
marrow cultures can support myelopoiesis and B lymphopoiesis. Journal of
immunology 138: 1082–1087.
50. Fortina P, Surrey S (2008) Digital mRNA profiling. Nature biotechnology 26:
293–294.
C/EBPb Modifications and Myeloid Reprogramming
PLOS ONE | www.plosone.org 9 June 2013 | Volume 8 | Issue 6 | e65169
